Sangamo, CRISPR stocks slide after report of data from early stage trial
Shares of Sangamo Therapeutics (SGMO) are plunging after the company presented interim data from the Phase 1/2 EMPOWERS Study evaluating the SB-318 zinc finger nuclease in vivo genome editing product candidate in patients with MPS II, also known as Hunter syndrome. Concurrent with the press release regarding the data, STAT's Adam Feuerstein quoted Sandy Macrae, Sangamo's CEO, as having said: "First and foremost, we must think about the patients we're treating, which is why it's fair to conclude that the results we're showing from our low and middle doses are not good enough." Following the presentation of the data, shares of Sangamo are down $3.24, or 27%, to $8.78. Crispr Therapeutics (CRSP), Editas Medicine (EDIT) and Intellia Therapeutics (NTLA), which are all publicly-traded companies investigating using CRISPR technology for disease treatments, are also sliding. Crispr shares are down 7%, Editas shares are down 6% and Intellia shares are down 4% following the release of Sangamo's data.